NCT01592695 | Iowa City Veterans Affairs Medical Center|US Department of Veterans Affairs | Cigarette Smoking | June 2012 | Phase 2 |
NCT04015414 | University of Zagreb|University of Ljubljana School of Medicine, Slovenia|University of Zagreb School of Medicine|Harvard Medical School (HMS and HSDM) | Smoking Cessation | July 14, 2020 | Phase 3 |
NCT04225052 | Yuhan Corporation|Chonbuk National University Hospital | Healthy Volunteer | December 19, 2019 | Phase 1 |
NCT02202499 | H. Lee Moffitt Cancer Center and Research Institute|James and Esther King Biomedical Research Program|Pfizer | Smoking Cessation|Tobacco Dependence | July 17, 2014 | Early Phase 1 |
NCT01509547 | Medical University of South Carolina | Nicotine Dependence | August 2012 | Phase 3 |
NCT02193256 | Yale University|National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Cigarette Smoking|Alcohol Use Disorders | July 2014 | Early Phase 1 |
NCT00141206 | Pfizer | Smoking Cessation | May 2003 | Phase 3 |
NCT00781599 | Nikki Nollen, PhD, MA|University of Kansas Medical Center | Smokers | October 2008 | Not Applicable |
NCT04135937 | VA Office of Research and Development | Human Immunodeficiency Virus|Smoking | November 18, 2019 | Phase 4 |
NCT01098955 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) | Head and Neck Cancer|Smoking Cessation | March 24, 2010 | Early Phase 1 |
NCT02933372 | University of Michigan | Parkinson´s Disease | October 5, 2015 | Phase 2 |
NCT01898195 | NYU Langone Health | Tobacco Use Cessation | March 2013 | Not Applicable |
NCT00661765 | Pfizer | Smoking Cessation | April 2008 | Phase 1 |
NCT00452894 | Pfizer | Smoking | March 2007 | Phase 1 |
NCT01027754 | Albert Einstein College of Medicine|National Center for Research Resources (NCRR) | Smoking Cessation|Substance-Related Disorders | August 2009 | Phase 4 |
NCT00802919 | Nathan Kline Institute for Psychiatric Research | Schizophrenia|Cigarette Smoking | September 2008 | Phase 4 |
NCT01694732 | University Hospital, Brest | Chronic Obstructive Pulmonary Disease|COPD Exacerbation|Smoking | August 2012 | Phase 3 |
NCT03630614 | Assistance Publique - Hôpitaux de Paris | Smoking Cessation|Smoking, Cigarette|Electronic Cigarette | October 17, 2018 | Phase 3 |
NCT01061710 | Pfizer | Smoking Cessation | July 2010 | |
NCT01243203 | University Health Network, Toronto|Pfizer | Smoking | November 2007 | Not Applicable |
NCT01312909 | Pfizer | Smoking Cessation | April 2011 | Phase 4 |
NCT01303861 | Duke University|National Institute on Drug Abuse (NIDA)|Philip Morris USA, Inc. | Nicotine Dependence | March 2011 | Phase 3 |
NCT00282984 | Pfizer | Smoking Cessation | February 2006 | Phase 3 |
NCT00743847 | Pfizer | Schizophrenia | March 2009 | Phase 2 |
NCT02271919 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) | Cigarette Smoker|Tobacco Use Disorder | May 14, 2015 | Phase 4 |
NCT03059563 | University of California, Los Angeles | Dopamine D2+3 Receptor Availability|Cognitive Function|Methamphetamine Abuse | January 11, 2018 | Phase 1 |
NCT00813917 | Mayo Clinic|National Institutes of Health (NIH) | Nicotine Dependence | February 2009 | Not Applicable |
NCT00644969 | Pfizer | Smoking Cessation | May 2008 | Phase 3 |
NCT01574703 | Pfizer | Smoking Cessation | May 2012 | Phase 4 |
NCT01011907 | University of California, San Francisco|National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Substance Dependence | January 2010 | Not Applicable |
NCT04083144 | Centre for Addiction and Mental Health|Pfizer|Brainsway | Tobacco Use Disorder|Smoking Cessation | August 22, 2019 | Not Applicable |
NCT02892110 | Medical University of South Carolina|National Institute on Drug Abuse (NIDA) | Substance Use Disorder | February 13, 2017 | Phase 2 |
NCT01800019 | Ottawa Hospital Research Institute|Canadian Institutes of Health Research (CIHR)|CIHR Canadian HIV Trials Network | HIV|Smoking Cessation | January 2014 | Phase 3 |
NCT04525755 | Medical University of South Carolina | Smoking|Smoking Cessation|Tobacco Smoking|Cigarette Smoking | February 8, 2021 | Phase 1|Phase 2 |
NCT02681848 | University of Bristol | Smoking Cessation|Cardiovascular Disease|Respiratory Disease|Myocardial Infarction|Depression|Anxiety | September 1, 2006 | |
NCT00889720 | Pfizer | Smoking Cessation | November 2009 | Phase 4 |
NCT05997225 | Albert Einstein College of Medicine|FDNY World Trade Center Health Program | Tobacco Use|Tobacco Smoking|Tobacco Use Cessation | November 2023 | Phase 4 |
NCT01141855 | The Queen Elizabeth Hospital | Tobacco Use Disorder | May 2008 | Phase 2|Phase 3 |
NCT02460900 | University of Maryland, Baltimore|National Heart, Lung, and Blood Institute (NHLBI) | Smoking|HIV | July 2016 | Phase 3 |
NCT02307045 | University of Athens | Smoking Cessation | December 3, 2014 | Phase 4 |
NCT03507127 | Brown University | Tobacco Dependence | May 1, 2018 | Phase 2 |
NCT00741884 | Pfizer | Smoking Cessation | August 2010 | Phase 2 |
NCT03688802 | Oyster Point Pharma, Inc. | Dry Eye Disease | September 25, 2018 | Phase 2 |
NCT02723162 | Medical University of South Carolina | Nicotine Dependence, Cigarettes | May 4, 2016 | Phase 2 |
NCT00702793 | University of British Columbia|Provincial Health Services Authority | Schizophrenia|Schizoaffective|Psychosis | April 2008 | Phase 4 |
NCT01093365 | Centre for Addiction and Mental Health|Pfizer | Schizophrenia|Schizoaffective Disorder | March 2010 | Phase 2 |
NCT00749944 | Pfizer | Smoking Cessation | September 2008 | Phase 4 |
NCT02351167 | Washington University School of Medicine|National Institutes of Health (NIH)|National Institute on Drug Abuse (NIDA) | Smoking Cessation | May 20, 2015 | Phase 4 |
NCT01406223 | Duke University|National Institute on Drug Abuse (NIDA) | Nicotine Dependence | July 2011 | Phase 3 |
NCT01387425 | Universita degli Studi di Catania | Smoking Cessation|Diabetes | June 2011 | Not Applicable |
NCT02393547 | Mayo Clinic | Tobacco Use Disorder|Weight Gain | September 2013 | Phase 1|Phase 2 |
NCT03538808 | University of Alabama at Birmingham | Medication Adherence | November 6, 2018 | Phase 4 |
NCT00992771 | University of South Florida|National Ataxia Foundation|Bob Allison Ataxia Research Center (BAARC)|Pfizer | Spinocerebellar Ataxia Type 3 | October 2009 | Phase 2 |
NCT01456936 | Pfizer|GlaxoSmithKline | Smoking Cessation | November 2011 | Phase 4 |
NCT02994082 | Mark Vander Weg|Iowa City VA Health Care System|Iowa City Veterans Affairs Medical Center | Smokeless Tobacco|Nicotine Dependence | December 2016 | Not Applicable |
NCT02360631 | Lisa Sanderson Cox, PhD|National Institute on Drug Abuse (NIDA)|University of Kansas Medical Center | Smoking Cessation | July 29, 2015 | Phase 4 |
NCT01623505 | Ottawa Heart Institute Research Corporation|Heart and Stroke Foundation of Ontario | Smoking Cessation|Psychiatric Illness | June 2010 | Phase 4 |
NCT00921388 | UConn Health|National Institutes of Health (NIH)|National Institute on Drug Abuse (NIDA) | Nicotine Dependence|Smoking Cessation | March 2009 | Not Applicable |
NCT00492349 | University of Maryland, Baltimore|Stanley Medical Research Institute | Schizophrenia|Schizoaffective Disorder|Schizophreniform Disorder | May 2007 | Phase 4 |
NCT02146911 | Centre for Addiction and Mental Health|Global Research Awards for Nicotine Dependence (GRAND) | Tobacco Use Disorder|Nicotine Dependence | May 1, 2014 | Not Applicable |
NCT00744978 | Pfizer | Alzheimer´s Disease | July 2009 | Phase 2 |
NCT01104636 | Pfizer | Smoking Cessation | May 2010 | |
NCT04167306 | Vastra Gotaland Region | Alcohol Use Disorder|Alcoholism|Alcohol Dependence | March 4, 2019 | Phase 2 |
NCT00523445 | Inje University|Stanley Medical Research Institute | Schizophrenia | September 2007 | Phase 3 |
NCT01710137 | University of Pennsylvania|National Institute on Drug Abuse (NIDA) | Nicotine Dependence | October 2012 | Phase 3 |
NCT00673595 | Mayo Clinic | Smoking | March 2007 | Not Applicable |
NCT00594204 | Pfizer | Smoking Cessation | April 2008 | Phase 4 |
NCT01143857 | Jennifer Plebani|National Institute on Drug Abuse (NIDA)|University of Pennsylvania | Cocaine Dependence | June 2010 | Phase 2 |
NCT00948155 | University of Pennsylvania|Pfizer | Nicotine Dependence | January 2009 | Phase 4 |
NCT01071187 | Johannes Gutenberg University Mainz|Pfizer | Alcohol Dependence | March 2010 | Phase 2 |
NCT00669240 | Pfizer | Smoking Cessation | November 2007 | |
NCT04199117 | University of Wisconsin, Madison|National Cancer Institute (NCI) | Smoking, Cigarette|Smoking Cessation | March 11, 2020 | Phase 4 |
NCT04176172 | University of Pennsylvania|National Cancer Institute (NCI)|Northwestern University | HIV+AIDS|Nicotine Dependence | February 17, 2020 | Phase 3 |
NCT01571167 | Baylor College of Medicine|National Institute on Drug Abuse (NIDA) | Methamphetamine Dependence|Methamphetamine Abuse|Substance Abuse | January 2011 | Phase 1 |
NCT00756275 | Brown University|National Institute on Drug Abuse (NIDA) | Smoking Cessation|Nicotine Dependence | January 2009 | Not Applicable |
NCT04018378 | Korea University Anam Hospital | Healthy | January 6, 2017 | Phase 1 |
NCT00879177 | UConn Health|National Institute on Drug Abuse (NIDA) | Cigarette Smoking|Hypertension | April 2009 | Phase 4 |
NCT00635401 | Pfizer | Smoking | May 2004 | Phase 2 |
NCT03809897 | Hospital Universitari Vall d´Hebron Research Institute|Clínica Galatea|Hospital Sant Rafael|Hospital de Sant Pau | Tobacco Use Cessation|Psychiatric Disorders | January 2019 | Phase 4 |
NCT01850953 | Centre for Addiction and Mental Health|Pfizer | Craving|Smoking|Schizophrenia | June 2013 | Phase 4 |
NCT01146613 | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Alcoholism | February 2011 | Phase 2 |
NCT01632189 | Centre for Addiction and Mental Health|Ontario Lung Association|Pfizer | Nicotine Dependence | September 2012 | Not Applicable |
NCT00747643 | H. Lee Moffitt Cancer Center and Research Institute|Pfizer | Tobacco Dependence | September 2008 | Not Applicable |
NCT00731562 | Pfizer | Pharmacokinetics|Bioavailability|Smoking Cessation | July 2008 | Phase 1 |
NCT03742154 | Medical University of South Carolina | Smoking|Smoking Cessation|Smoking, Tobacco|Smoking, Cigarette | December 3, 2018 | Early Phase 1 |
NCT00948649 | University of Pennsylvania|AstraZeneca | Nicotine Dependence | September 2006 | Phase 4 |
NCT02698215 | University of California, Los Angeles|National Institute on Drug Abuse (NIDA) | Nicotine Dependence|Alcohol Use Disorder | May 2016 | Phase 2 |
NCT05294263 | VA Office of Research and Development | Tobacco Use Disorder|Cannabis Use Disorder | April 17, 2023 | Phase 2 |
NCT00150228 | Pfizer | Smoking Cessation | December 2001 | Phase 2 |
NCT00525837 | Butler Hospital|Brown University | Depressive Disorder|Smoking | September 2007 | Not Applicable |
NCT00774605 | Pfizer | Smoking Cessation | December 2008 | Phase 1 |
NCT00731055 | New York State Psychiatric Institute|National Institute on Drug Abuse (NIDA) | Nicotine Dependence | February 2008 | Phase 2 |
NCT00695500 | Vijay Ramchandani, Ph.D.|National Institute on Alcohol Abuse and Alcoholism (NIAAA)|National Institutes of Health Clinical Center (CC) | Alcohol Drinking | June 2008 | Phase 1|Phase 2 |
NCT01184664 | Queen Mary University of London | Tobacco Dependence|Smoking Cessation | April 2011 | Phase 3 |
NCT01680887 | University of Pennsylvania | Cocaine Dependence | August 2012 | Phase 2 |
NCT00580645 | Yale University|National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Alcohol Drinking | April 2007 | Phase 2 |
NCT03069768 | Duke University|Intelligent Automation, Inc.|National Institute on Drug Abuse (NIDA) | Nicotine Dependence | April 2018 | Phase 1 |
NCT00713479 | University of California, Los Angeles|National Institute on Drug Abuse (NIDA) | Methamphetamine Addiction|Crystal Meth Addiction|Amphetamine Addiction | July 2008 | Phase 1 |
NCT02744417 | Claudio Mendes Pannuti|University of Sao Paulo | Periodontitis | August 2010 | Not Applicable |
NCT00794573 | Mark Eisenberg|Unity Health Toronto|Sunnybrook Health Sciences Centre|Queen Elizabeth II Health Sciences Centre|McGill University | Acute Coronary Syndrome | September 2009 | Phase 3 |
NCT00790569 | Butler Hospital|National Cancer Institute (NCI) | Bladder Cancer|Cervical Cancer|Esophageal Cancer|Gastric Cancer|Head and Neck Cancer|Kidney Cancer|Leukemia|Liver Cancer|Lung Cancer|Pancreatic Cancer|Tobacco Use Disorder | September 2008 | Not Applicable |
NCT02894957 | Shaare Zedek Medical Center | Smoking Cessation | October 2019 | Phase 4 |
NCT04036292 | Oyster Point Pharma, Inc. | Dry Eye Disease (DED) | July 23, 2019 | Phase 3 |
NCT04957758 | Oyster Point Pharma, Inc. | Neurotrophic Keratopathy | June 17, 2021 | Phase 2 |
NCT01244061 | Pfizer | Smoking Cessation | December 2010 | Phase 4 |
NCT02991781 | Aristotle University Of Thessaloniki|AAI Scientific Cultural Services Ltd (AAISCS)|NATIONAL ASSOCIATION OF GENERAL PRACTITIONERS IN BULGARIA | Chronic Obstructive Pulmonary Disease (COPD)|Asthma|Smoking | January 2017 | Not Applicable |
NCT00773422 | Yale University|National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Smoking | January 2008 | Phase 2 |
NCT02562521 | Yale University | Smoking Cessation | September 2015 | Phase 4 |
NCT04590404 | Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI)|National Institutes of Health (NIH) | Smoking | November 17, 2020 | Phase 3 |
NCT04595318 | Albert Einstein College of Medicine | Cannabis Dependence|Tobacco Dependence | January 2015 | Phase 4 |
NCT00143299 | Pfizer | Smoking Cessation | October 2003 | Phase 3 |
NCT01892813 | Mark Vander Weg|VA Office of Research and Development|University of Iowa | Nicotine Dependence|Tobacco Use | July 2013 | Phase 3 |
NCT03176784 | University of Wisconsin, Madison|Washington University School of Medicine|National Heart, Lung, and Blood Institute (NHLBI) | Tobacco Dependence | November 11, 2017 | Phase 4 |
NCT03227679 | Vanderbilt University Medical Center | Tobacco Use|Tobacco Use Cessation | May 18, 2016 | Not Applicable |
NCT01532232 | Memorial Sloan Kettering Cancer Center|Pfizer | Breast Cancer|Tobacco Dependence | February 2012 | |
NCT00860028 | Yale University|National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Nicotine Dependence|Smoking|Heavy Drinking | October 2008 | Phase 2 |
NCT02683161 | Johns Hopkins University | Cigarette Smoking|Obesity | October 2015 | Phase 2 |
NCT05514041 | Stephenson Eye Associates | Dry Eye Disease | August 29, 2022 | Phase 4 |
NCT00527150 | Pfizer | Smoking Cessation | October 2007 | Phase 1 |
NCT01169610 | Mayo Clinic | Alcoholism|Nicotine Dependence | January 2011 | Phase 3 |
NCT03897439 | University of Kansas Medical Center|National Institute on Drug Abuse (NIDA) | Smoking Cessation | May 1, 2019 | Phase 3 |
NCT01538394 | Josep Maria Ramon Torrell, PhD|Hospital Universitari de Bellvitge | Smoking Cessation | January 2012 | Phase 4 |
NCT00150254 | Pfizer | Smoking Cessation | September 2001 | Phase 2 |
NCT00959972 | Ottawa Heart Institute Research Corporation|Heart and Stroke Foundation of Ontario | Coronary Heart Disease | April 2009 | Phase 4 |
NCT00749658 | University of Minnesota|National Institute on Drug Abuse (NIDA)|Pfizer | Nicotine Dependence|Nicotine Withdrawal | November 2008 | Phase 2|Phase 3 |
NCT01151813 | University of Pennsylvania|National Institute on Drug Abuse (NIDA) | Alcohol Dependence|Cocaine Dependence | July 2010 | Phase 2 |
NCT04631874 | CTC Bio, Inc. | Smoking Cessation|Pharmacokinetics | July 24, 2019 | Phase 1 |
NCT00143364 | Pfizer | Smoking Cessation | June 2003 | Phase 3 |
NCT01341080 | Rush University Medical Center | Parkinson Disease | December 28, 2010 | Phase 2 |
NCT00944554 | Johns Hopkins University|Pfizer | Recurrence|Smoking Cessation|Substance-Related Disorders | October 2008 | Phase 4 |
NCT00709696 | University of Minnesota|National Institute on Drug Abuse (NIDA)|Pfizer | Nicotine Dependence | April 2008 | Not Applicable |
NCT00554840 | University of Maryland, Baltimore|National Institute on Drug Abuse (NIDA) | Cigarette Smoking|Schizophrenia | November 2007 | Phase 2 |
NCT01330043 | Stanford University|National Institute on Drug Abuse (NIDA) | Smoking Cessation | March 2010 | Phase 4 |
NCT02551692 | Duke University|National Institutes of Health (NIH)|National Institute on Drug Abuse (NIDA) | Cigarette Smoking | January 2016 | Not Applicable |
NCT00894166 | Duke University|Philip Morris USA, Inc. | Smoking Cessation | May 2009 | Phase 3 |
NCT01309685 | National Institute on Drug Abuse (NIDA)|National Institutes of Health Clinical Center (CC) | Drug Addiction | February 13, 2011 | Phase 1 |
NCT00606892 | Yale University|US Department of Veterans Affairs|National Institute on Drug Abuse (NIDA) | Smoking Cessation | August 2007 | Not Applicable |
NCT01308671 | General Hospital of Chinese Armed Police Forces | Coronary Artery Disease | October 2010 | Not Applicable |
NCT01772641 | Icahn School of Medicine at Mount Sinai|National Institute on Drug Abuse (NIDA) | Nicotine Addiction | December 2012 | Phase 4 |
NCT02501265 | Duke University|National Institute on Drug Abuse (NIDA)|Pfizer | Nicotine Dependence | June 6, 2017 | Phase 2 |
NCT00733967 | Baylor College of Medicine|National Institute on Drug Abuse (NIDA) | Methamphetamine Dependence|Substance Abuse|Methamphetamine Abuse | January 2008 | Phase 1 |
NCT00813800 | Mark Frye|Pfizer|Mayo Clinic | Smoking|Bipolar Disorder|Depression | January 2009 | Not Applicable |
NCT02147132 | University of Cincinnati | Cigarette Smoking|Methadone Maintenance | March 2016 | Phase 4 |
NCT00507728 | M.D. Anderson Cancer Center|National Institutes of Health (NIH)|National Institute on Drug Abuse (NIDA) | Tobacco Use Disorder|Smoking Cessation | December 8, 2005 | Phase 2|Phase 3 |
NCT01836276 | Nikki Nollen, PhD, MA|National Institute on Drug Abuse (NIDA)|Pfizer|University of Kansas Medical Center | Smoking Cessation | February 2013 | Phase 4 |
NCT01560507 | Duke University|Philip Morris USA, Inc. | Cigarette Smoking|Nicotine Dependence | May 2012 | Phase 2|Phase 3 |
NCT02922387 | General Hospital of Kavala|University of Thessaly | Pulmonary Disease, Chronic Obstructive|Asthma|Community Acquired Pneumonia | May 2012 | Phase 4 |
NCT00621777 | Massachusetts General Hospital|National Institute on Drug Abuse (NIDA) | Schizophrenia|Schizoaffective Disorder|Bipolar Disorder|Smoking | February 2008 | Phase 4 |
NCT01531049 | Tuula Toljamo|University of Oulu|University of Helsinki | Smoking Cessation|Smoking|Habits | May 2012 | Phase 2|Phase 3 |
NCT01228175 | The Mind Research Network|National Institute on Drug Abuse (NIDA) | Smoking Addiction | March 2010 | Phase 4 |
NCT01624428 | Yale University | Tobacco Use Disorders | June 2012 | Phase 1 |
NCT01347112 | Mayo Clinic | Smoking|Tobacco Dependence|Alcohol Dependence | June 2011 | Phase 2|Phase 3 |
NCT03035708 | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Alcohol Use Disorder | May 1, 2017 | Phase 1|Phase 2 |
NCT00781755 | VA Boston Healthcare System | Tobacco Use Disorder | | Phase 4 |
NCT02412631 | Mayo Clinic|National Institute on Drug Abuse (NIDA) | Obesity|Smoking Cessation | June 15, 2016 | Phase 2|Phase 3 |
NCT05576415 | Ji Xing Pharmaceuticals (Shanghai) Co., Ltd.|Oyster Point Pharma, Inc. | Dry Eye Disease | December 7, 2022 | Phase 1 |
NCT05700422 | University of Pennsylvania|Oyster Point Pharma, Inc. | Sjogren´s Syndrome|Dry Eye | May 1, 2023 | Phase 4 |
NCT01286584 | Centre for Addiction and Mental Health|Ontario Lung Association | Smoking Cessation|Alcohol Abuse | June 2011 | Phase 4 |
NCT05413122 | Johns Hopkins University|Colorado State University|New York University|Perinatal HIV Research Unit of the University of the Witswatersrand|National Cancer Institute (NCI) | Smoking Cessation|HIV|Comorbidities and Coexisting Conditions | September 1, 2023 | Phase 2|Phase 3 |
NCT00580853 | Yale University|National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Smoking Lapse Behavior | April 2007 | Phase 2 |
NCT03841292 | Centre for Addiction and Mental Health | Tobacco Dependence|Smoking Cessation|Tobacco Smoking|Tobacco Use Disorder|Substance Use Disorders|Molecular Mechanisms of Pharmacological Action|Physiological Effects of Drugs | October 1, 2018 | Not Applicable |
NCT00502216 | Yale University|National Institute on Alcohol Abuse and Alcoholism (NIAAA)|National Institute on Drug Abuse (NIDA) | Smoking|Nicotine Dependence | July 2007 | Phase 1|Phase 2 |
NCT04403399 | University of Michigan | Parkinson´s Disease | June 29, 2017 | Phase 2 |
NCT01023659 | Centre for Addiction and Mental Health|Ontario Ministry of Health and Long Term Care | Tobacco Use Disorder|Smoking|Smoking Cessation | April 2010 | Phase 4 |
NCT02634281 | Shaare Zedek Medical Center | Smoking Cessation | February 2016 | Phase 4 |
NCT00789074 | Queen Mary University of London | Tobacco Dependence|Smoking Cessation | July 2009 | Phase 3 |
NCT00918307 | ANRS, Emerging Infectious Diseases|Pfizer | HIV Infections|Tobacco Dependence | October 2009 | Phase 3 |
NCT05703672 | University of Kansas Medical Center | Smoking Reduction | June 30, 2023 | Phase 3 |
NCT00937235 | University of Pennsylvania|National Institute on Drug Abuse (NIDA) | Cigarette Smoking|Nicotine Dependence|Post-traumatic Stress Disorder|Tobacco Use Disorder | January 2009 | Phase 2 |
NCT01413516 | Stanford University|Pfizer | Smoking Cessation | August 2011 | Phase 2 |
NCT00835900 | Roswell Park Cancer Institute|Pfizer | Smoking Cessation | March 2009 | Phase 2 |
NCT00934024 | Medical University of South Carolina | Nicotine Dependence | April 2009 | Not Applicable |
NCT04089982 | Duke University | Smoking Cessation|Smoking Behaviors|Smoking | November 4, 2019 | Phase 4 |
NCT00567008 | University of Pennsylvania|National Institute on Drug Abuse (NIDA) | Cocaine Dependence | December 2007 | Phase 2 |
NCT02151591 | Yale University|National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Nicotine Dependence|Cigarette Smoking|Alcohol Consumption|Heavy Drinking | March 1, 2017 | Phase 1 |
NCT00580398 | Massachusetts General Hospital|National Cancer Institute (NCI) | Lung Cancer | January 2008 | Phase 1|Phase 2 |
NCT05786547 | University of Colorado, Denver|National Cancer Institute (NCI) | Human Immunodeficiency Virus|Smoking Cessation|Smoking, Tobacco | October 1, 2023 | Phase 3 |
NCT02582008 | Wake Forest University Health Sciences|National Cancer Institute (NCI) | Current Smoker|Head and Neck Squamous Cell Carcinoma|Hypopharyngeal Squamous Cell Carcinoma|Laryngeal Squamous Cell Carcinoma|Nasopharyngeal Carcinoma|Oral Cavity Squamous Cell Carcinoma|Oropharyngeal Squamous Cell Carcinoma | January 2016 | Early Phase 1 |
NCT05694637 | University of Maryland, Baltimore|University of Kentucky|University of Maryland, Baltimore County|University of Maryland, College Park | Smoking Cessation|Hiv | July 25, 2023 | Phase 4 |
NCT02378714 | Northwestern University|National Cancer Institute (NCI) | Nicotine Dependence|Major Depressive Disorder | July 24, 2015 | Phase 4 |
NCT04725617 | University of Arizona|University of Delaware | HIV|Sleep|Smoking Cessation|Cardiovascular Diseases | November 16, 2021 | Not Applicable |
NCT00694044 | Pfizer | Healthy|Non-Smoking | April 2008 | Phase 1 |
NCT00906386 | Vancouver Coastal Health|British Columbia Centre of Excellence for Women´s Health | Smoking | May 2009 | Phase 2 |
NCT04011280 | University of California, San Diego|Veterans Medical Research Foundation|University of California | Bipolar Disorder|Schizophrenia|Schizoaffective Disorder|Nicotine Dependence | August 12, 2019 | Phase 4 |
NCT00141167 | Pfizer | Smoking Cessation | February 2005 | Phase 3 |
NCT01444131 | University of Stellenbosch|QuitSupport | Tobacco Dependence | April 2011 | Phase 2 |
NCT02856581 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)|Pfizer | Lung Carcinoma | September 29, 2017 | Phase 3 |
NCT02473562 | Amsterdam UMC, location VUmc|Centre for Human Drug Research, Netherlands | Parkinson´s Disease | May 2013 | Phase 4 |
NCT03262662 | State University of New York at Buffalo|National Cancer Institute (NCI)|Pfizer | Tobacco Smoking | October 1, 2017 | Phase 3 |
NCT02233231 | Vibeke Backer|Bispebjerg Hospital | Asthma | August 2011 | Phase 4 |
NCT04445662 | Massachusetts General Hospital|National Cancer Institute (NCI)|National Institutes of Health (NIH) | Tobacco Smoking | June 10, 2021 | Not Applicable |
NCT01093937 | Centre for Addiction and Mental Health|Canadian Tobacco Control Research Initiative|Canadian Institutes of Health Research (CIHR) | Nicotine Dependence | November 2009 | Not Applicable |
NCT00995033 | Maastricht University Medical Center|ZonMw: The Netherlands Organisation for Health Research and Development|Nabi Biopharmaceuticals | Smoking Behavior|Smoking Lapse Behavior|Smoking Relapse Behavior | October 2009 | Phase 2 |
NCT00977249 | University Hospital, Gentofte, Copenhagen|Pfizer | Tobacco Dependence | September 2009 | Phase 2|Phase 3 |
NCT01553136 | Yale University|Columbia University|National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Alcoholism|Alcohol Abuse|Smoking|Alcohol Drinking | September 2012 | Phase 2 |
NCT01010204 | K.N. Roy Chengappa|National Institute of Mental Health (NIMH)|Pfizer|University of Pittsburgh | Smoking Cessation|Bipolar Disorder | January 2010 | Phase 4 |
NCT00664755 | Medical University of South Carolina | Nicotine Dependence | July 2007 | Phase 2 |
NCT02575183 | American University of Beirut Medical Center|Pfizer | Nicotine Dependence | August 31, 2016 | Phase 4 |
NCT03362099 | University of Sao Paulo General Hospital|Fundação de Amparo à Pesquisa do Estado de São Paulo | Smoking Cessation|Genetic Predisposition | November 1, 2016 | Phase 4 |
NCT00705523 | University of Pennsylvania|National Institute on Drug Abuse (NIDA) | Alcoholism | June 2008 | Phase 2 |
NCT04738643 | University of Pennsylvania | Cancer|Tobacco Use|Smoking|Nicotine Dependence | June 28, 2022 | Not Applicable |
NCT00786149 | University of Minnesota | Tobacco Use Cessation | September 2007 | Phase 3 |
NCT00143286 | Pfizer | Smoking Cessation | April 2003 | Phase 3 |
NCT00371813 | Pfizer | Smoking Cessation | September 2006 | Phase 3 |
NCT04188106 | Rose Research Center, LLC|Foundation for a Smoke Free World INC | Smoking Cessation|Stress|Sleep Disturbance|Nausea | June 17, 2019 | Phase 4 |
NCT01000987 | Yale University | Alcohol Reactivity | October 2009 | Phase 2 |
NCT01011829 | University of California, Los Angeles|National Institute on Drug Abuse (NIDA) | Methamphetamine Dependence|Substance Abuse|Methamphetamine Abuse | November 2009 | Phase 2 |
NCT00727103 | State University of New York - Upstate Medical University|National Alliance for Research on Schizophrenia and Depression | Schizophrenia|Schizoaffective Disorder|Alcohol Dependence|Nicotine Dependence | July 2008 | Phase 4 |
NCT03980561 | Medical University of South Carolina | Cannabis Use Disorder | January 31, 2020 | Phase 2 |
NCT05367492 | Massachusetts General Hospital|National Institute on Drug Abuse (NIDA) | Vaping|Nicotine Dependence | June 22, 2022 | Phase 4 |
NCT00483002 | Pfizer | Smoking Cessation | June 2007 | |
NCT04072146 | Oyster Point Pharma, Inc. | Healthy Subjects | August 26, 2019 | Phase 1 |
NCT00595868 | University of Vermont Medical Center|Pfizer | Tobacco Use Disorder|Tobacco Use Cessation|Nicotine Dependence | March 2008 | Phase 2 |
NCT03495024 | Corporal Michael J. Crescenz VA Medical Center | Schizophrenia|Schizoaffective Disorder|Tobacco Smoking|Tardive Dyskinesia|Parkinsonism | January 1, 2019 | Phase 4 |
NCT00717093 | Pfizer | Tobacco Use Cessation | August 2008 | Phase 4 |
NCT01524627 | University of Pennsylvania|National Institute on Drug Abuse (NIDA)|National Institutes of Health (NIH) | Nicotine Dependence | December 2011 | Phase 2 |
NCT04694846 | Thomas Jefferson University | Lung Non-Small Cell Carcinoma|Head and Neck Squamous Cell Carcinoma | August 19, 2020 | Not Applicable |
NCT01639560 | Mayo Clinic|Pfizer | Smoking | January 2013 | Phase 4 |
NCT02957786 | University of Auckland, New Zealand|Lakes District Health Board|Brunel University | Smoking Cessation | September 18, 2017 | Phase 3 |
NCT03873246 | Oyster Point Pharma, Inc. | Dry Eye Disease | February 18, 2019 | Phase 2 |
NCT00285012 | Pfizer | Smoking Cessation | May 2006 | Phase 3 |
NCT02488889 | University of California, Los Angeles | Cigarette Smoking|Alcohol Consumption | August 2015 | Phase 4 |
NCT05378945 | Ji Xing Pharmaceuticals (Shanghai) Co., Ltd.|Oyster Point Pharma, Inc. | Dry Eye Disease | July 22, 2022 | Phase 3 |
NCT00808015 | Pfizer | Smoking Cessation | February 2009 | |
NCT00907218 | Massachusetts General Hospital | Attention Deficit+Hyperactivity Disorder|Smoking Cessation | April 2009 | Phase 4 |
NCT01756885 | University of Pennsylvania | Nicotine Dependence | January 2013 | Phase 3 |
NCT01553084 | University of Wisconsin, Madison|National Institutes of Health (NIH)|National Heart, Lung, and Blood Institute (NHLBI) | Smoking Cessation|Smoking|Nicotine Dependence | May 2012 | Phase 4 |
NCT04604509 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) | Cigarette Smoking-Related Carcinoma | August 4, 2020 | Phase 4 |
NCT01436474 | Mayo Clinic | Chronic Pain|Opioid Dependence | June 2011 | Phase 1 |
NCT05257629 | Sir Mortimer B. Davis - Jewish General Hospital | Acute Coronary Syndrome | February 2, 2023 | Phase 3 |
NCT05642715 | Montefiore Medical Center|Westat|Massachusetts General Hospital|Truth Initiative|National Cancer Institute (NCI) | Hiv|Tobacco Use | March 2024 | Not Applicable |
NCT04198116 | Yale University|National Institute on Drug Abuse (NIDA) | Smoking Cessation | November 1, 2020 | Phase 2 |
NCT04317300 | Mayo Clinic | Vaping | February 1, 2023 | Early Phase 1 |
NCT01806779 | Duke University|National Institute on Drug Abuse (NIDA)|Philip Morris USA, Inc. | Nicotine Dependence | March 2013 | Phase 2 |
NCT02106637 | Sheba Medical Center|Hadassah Medical Organization|Barzilai Medical Center | Acute Coronary Syndrome|Smoking Cessation | October 2016 | Not Applicable |
NCT05541497 | Yale University | Smoking Cessation | November 4, 2022 | Phase 2 |
NCT01926041 | National Taiwan University Hospital|Ministry of Science and Technology, Taiwan | Diabetes Mellitus|Cigarette Smoking|Prediabetes | August 1, 2013 | Not Applicable |
NCT01934023 | Centre for Addiction and Mental Health|Pfizer | Schizophrenia | September 2013 | Phase 2 |
NCT02136498 | Kaiser Permanente|University of Michigan|University of California, Davis | Smoking Cessation|Medication Adherence | October 2014 | Not Applicable |
NCT00846859 | Sahlgrenska University Hospital, Sweden|Karolinska University Hospital|Malmö University | Alcohol Dependence | March 2009 | Phase 2 |
NCT01771627 | Roswell Park Cancer Institute|National Cancer Institute (NCI) | Tobacco Use Disorder | October 22, 2012 | Not Applicable |
NCT01314001 | University of Pennsylvania|National Institute on Drug Abuse (NIDA) | Nicotine Addiction | December 2010 | Phase 3 |
NCT05997901 | Centre for Addiction and Mental Health|Canadian Institutes of Health Research (CIHR)|Canadian Cancer Society (CCS) | Medication Adherence|Smoking Cessation | October 12, 2022 | Not Applicable |
NCT00943618 | M.D. Anderson Cancer Center|National Institutes of Health (NIH)|National Institute on Drug Abuse (NIDA)|Pfizer | Smoking Cessation | May 17, 2010 | Phase 3 |
NCT00143325 | Pfizer | Smoking Cessation | January 2005 | Phase 3 |
NCT02048917 | University of Kentucky|Kentucky Lung Cancer Research Program | Lung Cancer|Head and Neck Cancer | July 22, 2014 | Phase 1 |
NCT00691483 | Pfizer | Smoking Cessation | September 2008 | Phase 4 |
NCT01378858 | Albert Einstein College of Medicine|National Institute on Drug Abuse (NIDA) | Tobacco Use Disorder|Medication Adherence | July 2011 | Not Applicable |
NCT01365819 | University of California, Los Angeles | Methamphetamine Dependence|Substance Abuse|Methamphetamine Abuse | February 2012 | Phase 2 |
NCT01078298 | Pfizer | Smoking Cessation|Depression | March 2010 | Phase 4 |
NCT00828113 | University of Wisconsin, Madison|Pfizer | Smoking | January 2009 | Phase 4 |
NCT01098305 | University of Pennsylvania|All India Institute of Medical Sciences, New Delhi | Tobacco Use Disorder | April 2011 | Phase 2 |
NCT03557294 | Arizona State University|National Institute on Drug Abuse (NIDA)|Los Angeles Clinical Trials|University of Nevada, Reno|Pfizer | Tobacco Dependence|Withdrawal Symptoms|Smoking Cessation | May 7, 2018 | Phase 4 |
NCT01234142 | Pfizer | Smoking Cessation | November 2010 | Phase 1 |
NCT02797587 | Boston Medical Center|National Institute on Alcohol Abuse and Alcoholism (NIAAA) | HIV Infection|Alcohol Use|Smoking | July 19, 2017 | Phase 2|Phase 3 |
NCT04634071 | Joseph Valentino, MD|University of Kentucky | Smoking Cessation|Cancer, Treatment-Related | January 12, 2021 | Phase 2 |
NCT03365362 | Albert Einstein College of Medicine|National Institutes of Health (NIH)|Pfizer|National Institute on Drug Abuse (NIDA) | Tobacco Use Disorder|Opioid-use Disorder | October 25, 2018 | Phase 4 |
NCT02854800 | West Virginia University|Pfizer|National Institute on Drug Abuse (NIDA) | Smoking Cessation|Opioid Related Disorders | July 8, 2016 | Phase 2|Phase 3 |
NCT04490057 | Yale University|National Cancer Institute (NCI) | Tobacco Use Cessation | July 27, 2020 | Phase 4 |
NCT03722966 | University of Oklahoma|Pfizer | Smoking Cessation | December 2, 2019 | Phase 2 |
NCT00772941 | Pfizer | Smoking Cessation | February 2009 | |
NCT00803868 | University of South Florida|Friedreich´s Ataxia Research Alliance|Pfizer | Friedreich´s Ataxia | May 2009 | Phase 2|Phase 3 |
NCT00832806 | University of British Columbia|Pfizer | Additional, Effective Methods to Stop Smoking | January 2008 | Phase 1 |
NCT00701896 | Philip Diaz|National Heart, Lung, and Blood Institute (NHLBI)|Ohio State University | Smoking|HIV Infections | October 3, 2008 | Not Applicable |
NCT00895557 | University of Pennsylvania|National Institute on Drug Abuse (NIDA) | Varenicline and the Blunting of Cocaine Cues | December 2007 | Phase 2 |
NCT02162849 | M.D. Anderson Cancer Center|NAL PHARMA|Pfizer | Tobacco Use Cessation | December 14, 2015 | Phase 4 |
NCT00139750 | Pfizer | Smoking Cessation | December 2004 | Phase 2 |
NCT00873535 | Centre for Addiction and Mental Health|Canadian Institutes of Health Research (CIHR) | Tobacco Dependence|Alcohol Dependence | October 2008 | Not Applicable |
NCT04228965 | Medical University of South Carolina|National Cancer Institute (NCI)|National Institutes of Health (NIH) | Tobacco Use Disorder | January 28, 2020 | Phase 4 |
NCT01162239 | University of California, San Francisco|National Institute on Drug Abuse (NIDA)|Pfizer | Nicotine Dependence | May 2010 | Phase 3 |
NCT00937508 | University Health Network, Toronto|Pfizer | Smoking | June 2008 | Phase 4 |
NCT04249882 | University of California, Los Angeles|National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Alcohol Use Disorder | January 28, 2020 | Phase 2 |
NCT01013454 | Pfizer | Smoking Cessation | December 2009 | Phase 1 |
NCT03636061 | Oyster Point Pharma, Inc. | Dry Eye Disease | August 15, 2018 | Phase 2 |
NCT00150241 | Pfizer | Smoking Cessation | February 2000 | Phase 2 |
NCT02888444 | University of Auckland, New Zealand | Chronic Obstructive Pulmonary Disease|Smoking Cessation | July 31, 2017 | Phase 3 |
NCT00567320 | Yale University|National Institute on Drug Abuse (NIDA)|US Department of Veterans Affairs | Cocaine Dependence|Nicotine Dependence | March 2007 | Not Applicable |
NCT00548470 | Nathan Kline Institute for Psychiatric Research|University of Illinois at Chicago | Schizophrenia|Tobacco Use Disorder|Nicotine Dependance | June 2007 | Phase 4 |
NCT03553173 | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla|European Commission|Andaluz Health Service | Smoking Cessation|Health Behavior|Lifestyle-related Condition | October 24, 2016 | Not Applicable |
NCT01111149 | University of Minnesota|National Institutes of Health (NIH)|National Institute on Drug Abuse (NIDA) | Schizophrenia|Smoking Cessation | December 2009 | Phase 2 |
NCT01290445 | Pfizer|University of Aarhus|Karolinska Institutet | Malformations | September 13, 2007 | |
NCT00525928 | Butler Hospital|Brown University | Smoking|Depressive Disorder | October 2007 | Not Applicable |
NCT03521141 | Vanderbilt University Medical Center|Meharry Medical College|Tennessee State University | Tobacco Use Cessation | May 18, 2018 | Phase 2|Phase 3 |
NCT04188873 | University of Wisconsin, Madison|National Cancer Institute (NCI) | Nicotine Dependence | December 10, 2020 | Phase 4 |
NCT04210180 | Rose Research Center, LLC|Foundation for a Smoke Free World INC | Smoking Cessation|Harm Reduction | November 19, 2019 | Phase 2|Phase 3 |
NCT01474265 | Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH|University Medical Center Goettingen | Smoking Cessation | November 2011 | Phase 4 |
NCT00931021 | Yale University | Smoking Cessation | July 2009 | Early Phase 1 |
NCT00794365 | Pfizer | Smoking Cessation | July 2008 | |
NCT00301145 | SRI International|National Cancer Institute (NCI) | Unspecified Adult Solid Tumor, Protocol Specific | October 2005 | Not Applicable |
NCT00602927 | University of Pennsylvania|Pfizer|National Cancer Institute (NCI) | Nicotine Dependence | November 2007 | Not Applicable |
NCT01170338 | Newark Beth Israel Medical Center | Smoking|Acute Coronary Syndrome | January 2008 | Phase 4 |
NCT04191278 | Duke University|National Institute on Drug Abuse (NIDA) | HIV+AIDS|Smoking|Smoking Cessation|HIV | November 2021 | Phase 4 |
NCT00463918 | Pfizer | Smoking Cessation | May 2007 | Phase 1 |
NCT00587769 | Mayo Clinic | Smoking|Tobacco Use Disorder | July 2007 | Phase 3 |
NCT01370356 | Pfizer | Smoking Cessation | July 2011 | Phase 4 |
NCT01308736 | Rutgers, The State University of New Jersey|Pfizer | Tobacco Use Disorder | January 2011 | Not Applicable |
NCT01092702 | Mayo Clinic | Tobacco Abstinence | April 2008 | Phase 2|Phase 3 |
NCT01206010 | Queen Mary University of London | Tobacco Dependence|Smoking Cessation | July 2011 | Phase 3 |
NCT02859142 | University of Chicago|Pfizer | Smoking Cessation|Alcohol Drinking | March 29, 2018 | Phase 4 |
NCT00455650 | Massachusetts General Hospital|National Alliance for Research on Schizophrenia and Depression|The Bowman Family Foundation | Cognition in Schizophrenia | March 2007 | Not Applicable |
NCT00935818 | Mayo Clinic|National Cancer Institute (NCI)|University of Minnesota | Smoking | September 2009 | Phase 2|Phase 3 |